CD38 CHO Recombinant Cell Line (High, Medium or Low Expression)

Only %1 left
Catalog #
79615
As low as $7,370 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant clonal stable CHO cell line constitutively expressing full length human CD38 protein, also known as ADPRC1 (Genbank #NM_001775). Surface expression of CD38 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD38 expression (High, Medium, Low) to mimic different stages of cancer target cells with various CD38 expression levels.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Product Info
Storage and Usage
Citations
Host Cell Line
CHO K1 cell line, Chinese Hamster Ovary
Supplied As
Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
UniProt #
P28907
Mycoplasma Testing
This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Background
CD38 (cyclic ADP-ribose hydrolase 1, ADPRC1) is a glycoprotein and ectoenzyme which plays an important role in regulating intracellular calcium. CD38 is a highly attractive target antigen for immunotherapy because it is highly expressed on multiple myeloma cells, and at relatively low levels on normal lymphoid and myeloid cells. Expression of CD38 has also been associated with HIV infection, leukemia, and type II diabetes mellitus. CD38 CAR-T is a T cell product engineered by retroviral transduction to express a fully human CD38-specific CAR (chimeric antigen receptor). In 2015, the FDA approved daratumumab (Darzalex), a breakthrough therapy drug targeting CD38, for the treatment of multiple myeloma.